Oramed Pharmaceuticals Announces the Expansion of Its Scientific Board With a Prominent American Figure in Diabetes Research
01 February 2007 - 12:48AM
PR Newswire (US)
JERUSALEM, Israel, Jan. 31 /PRNewswire-FirstCall/ -- Oramed
Pharmaceuticals (OTC Bulletin Board: ORMP; Frankfurt: OJU) has
added the accomplished Derek LeRoith, MD PhD to its world class
scientific board. With contributions leading to over 500
publications, Dr. LeRoith is presently the Chief of the Division of
Endocrinology and Diabetes in the Department of Medicine at the Mt.
Sinai School of Medicine. Dr. LeRoith began his studies in Cape
Town, where he received both his medical degree and completed his
thesis for his PhD. His career in America started as the Chief of
the Diabetes Branch at the National Institute of Diabetes,
Digestive and Kidney Diseases in the National Institute of Health
in Maryland, and he is now serving as the Chief of the Division of
Endocrinology, Diabetes and Bone Diseases. He is a prominent member
in over 15 professional societies globally, including the Society
for Endocrinology, Metabolism and Diabetes of South Africa, the
European Association for the Study of Diabetes, and the American
Diabetes Association. Dr. LeRoith has been granted a number of
prominent administrative responsibilities, including positions
within the American Diabetes Association (President of the
Montgomery Chapter, President of the Washington D.C. Affiliate, the
Board of Directors, Chairperson of the Research and Grant Panel),
Chief of the Endocrine Consulting Services at the Clinical Center
of the National Institution of Health, President of the
International Society for Insulin-like Growth Factor Research, and
Board of Directors for the Endocrine Fellows Foundation, among many
others. His awards include, but are not limited to, Medal for
Physiology, the Bronte Stewart Award for PhD Thesis, British
Endocrine Society Transatlantic Medal, and multiple Memorial
Lectures. CEO Nadav Kidron states, "We are proud to have Dr. Derek
LeRoith join our board of directors with his vast experience
amongst the influential leaders in diabetic research in the United
States." As our studies progress, this will enable Oramed
Pharmaceuticals, Inc. to open doors and expand the knowledge of our
technology into international territory. About Oramed
Pharmaceuticals, Inc: Oramed Pharmaceuticals Inc. is an Israeli
based company focused on the development of oral delivery solutions
based on proprietary technology. Diabetes is one of the most
rapidly growing diseases in the world and is one that requires
constant and often unpleasant monitoring and drug therapy regimen.
Oramed is currently developing an orally soft gel insulin capsule
for the treatment of diabetes. The Company is also pursuing the
development of oral delivery solutions for other drugs and
vaccines. For more information on Oramed Pharmaceuticals please
visit our website: http://www.oramedpharma.com/ Investor Relations
Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri(646)
467-2252 http://www.oramedpharma.com/ DATASOURCE: Oramed
Pharmaceuticals, Inc. CONTACT: Investor Relations, Vinisha
Agnihotri, of Oramed Pharmaceuticals, Inc., +1-646-467-2252, or Web
site: http://www.oramedpharma.com/
Copyright